SC 38249
Latest Information Update: 13 Feb 1995
Price :
$50 *
At a glance
- Originator Pharmacia Corporation
- Class Antiplatelets
- Mechanism of Action Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders; Thrombosis